Evan Sehgal, MD
Interventional Cardiology · Hasbrouck Heights, NJNPI 1982671871
Payments from drug & device makers
Across 849 payments — averaging $70.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Esperion Therapeutics, Inc.$50K
- Medtronic$2K
- Amgen$1K
- Novartis$958
- Boehringer Ingelheim$925
- Amarin Pharma, Inc.$790
- plus $4K from 24 others
What the payments were for
- Speaking & faculty fees$38,23564%
- Travel & lodging$8,76615%
- Food & beverage$12,75421%
- Education$2780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Esperion Therapeutics, Inc. | 223 | $49,913 |
| Medtronic(2 entities) | 15 | $1,872 |
| Amgen | 93 | $1,399 |
| Novartis | 76 | $958 |
| Boehringer Ingelheim | 72 | $925 |
| Amarin Pharma, Inc. | 96 | $790 |
| AstraZeneca | 27 | $749 |
| Boston Scientific | 49 | $640 |
| Philips North America LLC | 18 | $479 |
| Pfizer | 30 | $447 |
| Johnson & Johnson | 34 | $305 |
| E.r. Squibb & Sons, L.L.C. | 27 | $297 |
| Merck | 18 | $288 |
| Regeneron Healthcare Solutions, Inc. | 18 | $242 |
| Alnylam Pharmaceuticals Inc. | 21 | $174 |
| Heartflow, Inc. | 9 | $144 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $86 |
| Novo Nordisk | 4 | $83 |
| Cvrx, Inc. | 2 | $57 |
| W. L. Gore & Associates, Inc. | 2 | $28 |
| Cardiva Medical, Inc. | 1 | $21 |
| Abbott | 1 | $18 |
| Bridgebio Pharma, Inc. | 1 | $17 |
| Irhythm Technologies, Inc. | 1 | $17 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $16 |
| Bardy Diagnostics, Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXLETOL$48,362
- NEXLIZET$48,132
- Micra$918
- FARXIGA$325
- WAINUA$325
- CareLink$200
- Reveal LINQ$196
- AURORA EV-ICD MRI SURESCAN$164
- CoreValve Evolut$162
- MyCareLink$102
How this compares
$60,034 in reported general payments places this provider in the 80th percentile of 166 interventional cardiology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 31 | $794,393 |
| EliquisApixaban | 370 | $457,845 |
| Repatha SureclickEvolocumab | 354 | $398,306 |
| Praluent PenAlirocumab | 319 | $356,897 |
| JardianceEmpagliflozin | 184 | $232,678 |
| XareltoRivaroxaban | 128 | $158,033 |
| FarxigaDapagliflozin Propanediol | 128 | $138,234 |
| NexlizetBempedoic Acid/Ezetimibe | 111 | $98,753 |
| EntrestoSacubitril/Valsartan | 32 | $42,022 |
| VascepaIcosapent Ethyl | 42 | $34,286 |
| VerquvoVericiguat | 18 | $23,968 |
| Colchicine | 290 | $23,310 |
| Rosuvastatin Calcium | 1,356 | $21,510 |
| Ezetimibe | 695 | $19,528 |
| Metoprolol Succinate | 982 | $17,446 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $447 | $1,252,238401 claims |
| Boehringer IngelheimJardiance | $925 | $232,678184 claims |
| Johnson & JohnsonXarelto | $305 | $158,033128 claims |
| AstraZenecaFarxiga | $749 | $138,234128 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $49,913 | $114,375128 claims |
| NovartisEntresto | $958 | $42,02232 claims |
| MerckVerquvo | $288 | $23,96818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 166 interventional cardiology providers in New Jersey.
Other interventional cardiology in Hasbrouck Heights
- Ramin HastingsHasbrouck Heights$355K
- Dinesh SingalSomerset$1.4M
- Ankitkumar PatelGlen Ridge$717K
- Matthew SayboltEatontown$671K
- Jaffar RazaSecaucus$537K
- Kintur SanghviBordentown$467K
- Ziad AbbudOcean$361K
- Ryan KapleHackensack$280K
- Haroon FarazTeaneck$269K
- Darshan GodkarCedar Knolls$260K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.